MHPS Successfully Tests Large-Scale High-Efficiency Gas Turbine Fueled by 30% Hydrogen Mix
A large-scale gas turbine for use in power generation under development by Mitsubishi Hitachi Power Systems, Ltd. (MHPS) has successfully passed a firing test using a 30% hydrogen fuel mix*1. The test results confirmed that by using MHPS’s proprietary burner, which was newly developed to burn hydrogen, stable combustion can be attained even when hydrogen is mixed with natural gas. Using a 30% hydrogen mixture, a reduction in carbon dioxide (CO2) emissions of 10% was achieved, compared to natural-gas-fired power generation.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180125005516/en/
Actual-pressure combustion testing facilities that carried out the hydrogen-mixed firing test (Photo: Business Wire)
The hydrogen-mixed firing test was carried out at MHPS’s Takasago Works, using actual-pressure combustion testing facilities, as part of a project of Japan’s New Energy and Industrial Technology Development Organization (NEDO) aimed at developing technologies for realizing a “hydrogen society.” In a hydrogen society, broad use is made of hydrogen—a clean, carbon-free energy that releases no greenhouse gases.
The firing test conditions called for a turbine inlet temperature of 1,600℃, equivalent to 700 megawatts (MW) of output, using the premix combustor of the natural-gas-fired J-Series gas turbines, which provides power generation efficiency above 63%. With a hydrogen mix of 30%, stable combustion was demonstrated while satisfying operable threshold values pertaining to nitrogen oxide (NOx) emissions, combustion oscillation, etc.*2
The stable hydrogen-mixed firing technology applied in the large-scale gas turbine uses MHPS’s proprietary dry low-NOx (DLN) combustor developed for this project as an improved version of the Company’s natural-gas-fired combustors. The combustion method is premixing, a field in which MHPS has abundant experience through its use of DLN combustors. The combustor’s fuel nozzle creates a rotational airflow that enables the formation of a more uniform premixed gas, leading to low NOx. Other than the combustor, the equipment currently in place can be used without modification, thereby curbing the potential costs of converting a natural-gas-fired power plant to a hydrogen plant.
In Japan, under the leadership of the Ministry of Economy, Trade and Industry and the Cabinet Office, efforts are underway to develop hydrogen as one of the nation’s core energies. Research and development of gas turbines fueled by hydrogen currently focuses on small and medium-size gas turbines for small-scale thermal power plants suited to distributed power generation or area cogeneration. Now, with successful testing toward use of hydrogen fuel in a large-scale gas turbine for large-scale thermal power plants, expectations are focusing on the new technology making a major contribution to easing the burden on the global environment during power generation. It marks the first step toward realizing a CO2-free hydrogen society, a key strategy set last December at the second meeting of Japan’s Ministerial Council on Renewable Energy, Hydrogen and Related Issues.
Following this successful test, MHPS will accelerate the development of hydrogen-fueled gas turbines and encourage hydrogen use by thermal power plant operators. Mitsubishi Heavy Industries Group is also a leader in CO2 capture and storage (CCS) technology, which is indispensable for supplying carbon-free hydrogen. By linking these technologies, the Group is poised to lead the development of an international supply chain spanning hydrogen supply, transport and storage, thereby contributing to realization of a hydrogen society.
The ratio of hydrogen content indicates volume ratio.
The NEDO project actually targets a 20% hydrogen mix. For testing purposes, a 30% mixture was used in order to secure ample tolerance for use in actual power plants. Going forward, efforts will continue to focus on improving mixed-combustion technology.
About Mitsubishi Hitachi Power Systems, Ltd.
Mitsubishi Hitachi Power Systems, Ltd. (MHPS), headquartered in Yokohama, Japan, is a joint venture formed in February 2014 by Mitsubishi Heavy Industries, Ltd. and Hitachi, Ltd. integrating their operations in thermal power generation systems and other related businesses. MHPS today ranks among the world’s leading suppliers of equipment and services to the power generation market, backed by 100 billion yen in capital and approximately 20,000 employees worldwide. The Company’s products include GTCC (gas turbine combined-cycle) and IGCC (integrated coal gasification combined-cycle) power plants, conventional gas/coal/oil-fired (thermal) power plants, boilers, generators, gas and steam turbines, geothermal power plants, AQCS (air quality control systems), power plant peripheral equipment and solid-oxide fuel cells (SOFC). For more information, please visit the Company's website at https://www.mhps.com/en/index.html
Mitsubishi Heavy Industries, Ltd.
Joseph Hood, +81-(0)3-6716-2168
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AURAK Gains SACSCOC Accreditation15.12.2018 10:49 | Pressemelding
The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/ AURAK delegation during the SACSCOC conference in New Orleans” (Photo: AETOSWire) SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now
Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41 | Pressemelding
Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl
Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42 | Pressemelding
Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00
Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00 | Pressemelding
Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu
Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07 | Pressemelding
Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha